RT Journal Article
SR Electronic
T1 Longitudinal Assessment of Solid Organ Transplant Recipients with SARS-CoV-2 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.11.21.24317576
DO 10.1101/2024.11.21.24317576
A1 Vuyk, Will
A1 Bobholz, Max
A1 Emmen, Isla
A1 Lail, Andrew
A1 Minor, Nicolas
A1 Bhimalli, Pavan
A1 Eickhoff, Jens C.
A1 Ries, Hunter J.
A1 Machkovech, Heather
A1 Wei, Wanting
A1 Weiler, Andrea
A1 Richardson, Alex
A1 DePagter, Carson
A1 VanSleet, Grace
A1 Bhasin, Maansi
A1 Kamal, Sarah
A1 Wolf, Sydney
A1 Virdi, Aanya
A1 Bradley, Taylor
A1 Gifford, Angela
A1 Benito, Melanie
A1 Shipe, Alex
A1 Mohamed, Rana
A1 Smith, Jeannina
A1 Wilson, Nancy
A1 Friedrich, Thomas C.
A1 O’Connor, David H.
A1 Garonzik-Wang, Jacqueline
YR 2024
UL http://medrxiv.org/content/early/2024/11/23/2024.11.21.24317576.abstract
AB Background Compared to immunocompetent individuals, those who are immunocompromised, including solid organ transplant (SOT) recipients, have higher SARS-CoV-2-related morbidity and mortality. We determined the duration of SARS-CoV-2 RNA positivity to evaluate viral persistence in SOT recipients.Methods This study prospectively followed SOT recipients who recently tested positive for SARS-CoV-2. The duration of viral RNA shedding in nasal swabs and stool samples was tracked, and viral genome sequencing was performed where possible. Persistent infection was defined as a positive nucleic acid amplification test (NAAT) for SARS-CoV-2 at 28 days or later after initial infection. This duration was chosen based on the CDC recommendation that immunocompromised individuals isolate for at least 20 days 1, compared to 10 days for non-immunocompromised individuals.Results Of 30 SOT recipients, 12 (40%) had SARS-CoV-2 RNA in nasal swabs or stool 28 or more days after the first positive SARS-CoV-2 test. IC-015 had high viral loads (Ct<30) at 28 days, with continued detection for 54 days.Conclusion In 12 of 30 SOT subjects, SARS-CoV-2 RNA was detected at or beyond 28 days post-detection (dpd), despite vaccination and antibody and/or antiviral treatment in most participants. Three subjects tested positive for SARS-CoV-2 RNA past 50 dpd. The CDC recommendation for 20 days of isolation may be insufficient for SOT recipients. Viral persistence in the setting of host immune suppression, coupled with exposure to antiviral treatments, raises concern about the selection of unusual viral variants.X (twitter) post Include Visual Abstract and following text:Compared to immunocompetent individuals, those who are immunocompromised, including solid organ transplant (SOT) recipients, have higher SARS-CoV-2-related morbidity and mortality. We determined the duration of SARS-CoV-2 RNA positivity to evaluate viral persistence in SOT recipients.This study prospectively followed SOT recipients who recently tested positive for SARS-CoV-2. The duration of viral RNA shedding in nasal swabs and stool samples was tracked, and viral genome sequencing was performed where possible. Persistent infection was defined as a positive nucleic acid amplification test (NAAT) for SARS-CoV-2 at 28 days or later after initial infection. This duration was chosen based on the CDC recommendation that immunocompromised individuals isolate for at least 20 days 1, compared to 10 days for non-immunocompromised individuals.In 12 of 30 SOT subjects, SARS-CoV-2 RNA was detected at or beyond 28 days post-detection (dpd), despite vaccination and antibody and/or antiviral treatment in most participants. Three subjects tested positive for SARS-CoV-2 RNA past 50 dpd. The CDC recommendation for 20 days of isolation may be insufficient for SOT recipients. Viral persistence in the setting of host immune suppression, coupled with exposure to antiviral treatments, raises concern about the selection of unusual viral variants.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCDC Contract Number: 200-2021-11060- FY21 BAA Topic 8 Wisconsin-Madison; 435100-A24-ELCProjE-00 Wisconsin Department of Health Services, ELC; Department of Surgery start up funds (JGW)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UW-Madison Health Sciences IRB of the University of Wisconsin gave ethical approval for this work, study ID 2022-0499.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesCDCCenters for Disease ControlCOVID-19coronavirus disease 2019Ctcycle thresholddpddays post detectionICimmunocompromisedNAnucleic acidNAATnucleic acid amplification testPCRpolymerase chain reactionPPMoVpepper mild mottle virusREDCapresearch electronic data captureRNAribonucleic acidRT-qPCRreverse transcribed quantitative polymerase chain reactionSARS-CoV-2severe acute respiratory syndrome coronavirus 1SOTsolid organ transplantvRNAviral RNA